# BAP1

Source: https://onco.cc/targets/bap1/  
OnCo record `bap1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BAP1 (Ubiquitin carboxyl-terminal hydrolase BAP1) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Mesothelioma, Biliary tract cancer and 5 more.

## Summary

Deubiquitinating enzyme that plays a key role in chromatin by mediating deubiquitination of histone H2A and HCFC1. Catalytic component of the polycomb repressive deubiquitinase (PR-DUB) complex, a complex that specifically mediates deubiquitination of histone H2A monoubiquitinated at 'Lys-120' (H2AK119ub1). Does not deubiquitinate monoubiquitinated histone H2B.

CIViC holds 19 clinical evidence items and 0 assertions across 10 variants, naming Olaparib, Vorinostat, Valproic Acid and Everolimus and others. Open Targets scores its association with cancer at 0.88 (direct and indirect evidence; datatypes genetic literature 0.89, affected pathway 0.91, literature 0.99, genetic association 0.76, somatic mutation 0.94, animal model 0.38). IntOGen calls it a driver in 23 cohorts (3 activating, 20 loss-of-function), covering Invasive Breast Carcinoma, Renal Clear Cell Carcinoma, Cervical Squamous Cell Carcinoma, Cholangiocarcinoma, Oesophageal Adenocarcinoma, Hepatocellular Carcinoma and others.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: BRCA1 associated deubiquitinase 1; Ubiquitin carboxyl-terminal hydrolase BAP1; hucep-6; KIAA0272; UCHL2
- Tags: cancer-genes-wave
- Symbol: BAP1
- Class: enzyme
- Biology: Deubiquitinating enzyme that plays a key role in chromatin by mediating deubiquitination of histone H2A and HCFC1. Catalytic component of the polycomb repressive deubiquitinase (PR-DUB) complex, a complex that specifically mediates deubiquitination of histone H2A monoubiquitinated at 'Lys-120' (H2AK119ub1). Does not deubiquitinate monoubiquitinated histone H2B. The PR-DUB complex is an epigenetic regulator of gene expression and acts as a transcriptional coactivator, affecting genes involved in development, cell communication, signalling, cell proliferation and cell viability. Antagonises PRC1 mediated H2AK119ub1 monoubiquitination. As part of the PR-DUB complex, associates with chromatin enriched in histone marks H3K4me1, H3K4me3, and H3K27Ac, but not in H3K27me3. Location: Cytoplasm; Nucleus; Chromosome (UniProt). Locus 3p21.1 (HGNC).
- Where found: Renal cell carcinoma: Open Targets association 0.68 with renal cell carcinoma (MONDO_0005086); CIViC evidence names this disease; Mesothelioma: Open Targets association 0.68 with malignant mesothelioma (MONDO_0006292); CIViC evidence names this disease; Biliary tract cancer: Open Targets association 0.64 with biliary tract cancer (MONDO_0003060); Hepatocellular carcinoma: Open Targets association 0.53 with hepatocellular carcinoma (MONDO_0007256); IntOGen driver in 3 cohorts (HCC); Gastric & gastro-oesophageal junction cancer: Open Targets association 0.54 with gastric cancer (MONDO_0001056); IntOGen driver in 1 cohort (STAD); Breast cancer: IntOGen driver in 1 cohort (BRCA)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 14 therapies; IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 20 cohorts; CIViC holds 19 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Malignant Mesothelioma; Renal Carcinoma.

## Sources

- HGNC HGNC:950: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:950
- UniProt Q92560: https://www.uniprot.org/uniprotkb/Q92560/entry
- NCBI Gene 8314: https://www.ncbi.nlm.nih.gov/gene/8314
- Ensembl ENSG00000163930: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163930

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Cervical cancer](https://onco.cc/cancers/cervical/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)

---
JSON: https://onco.cc/api/v1/entities/bap1.json